RTP Mobile Logo
Select Publications

Andorsky D et al. Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations. ASH 2021; Abstract 3599.

Brummendorf TH et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial. Leukemia 2022;36(7):1825-33. Abstract

Cortes J et al. Chronic myeloid leukaemia. Lancet 2021;398(10314):1914-26. Abstract

Cortes J et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial. Blood 2021;138(21):2042-50. Abstract

Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: Current status and future directions. J Hematol Oncol 2021;14(1):44. Abstract

Cortes JE et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial. Blood 2018;132(4):393-404. Abstract

Cortes JE et al. Trial in progress: A multicenter, open label, randomized, phase III study of asciminib (80 mg once daily) vs investigator-selected TKI in newly diagnosed adult patients with chronic myeloid leukemia in chronic phase. ASH 2021; Abstract 1478.

De Novellis D et al. The TKI era in chronic leukemias. Pharmaceutics 2021;13(12):2201. Abstract

Hughes T et al. Trial in progress: A phase III study of asciminib vs an investigator-selected TKI in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). EHA 2022; Abstract PB1904.

Kantarjian HM et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35(2):440-53. Abstract

Mahon F-X et al. FINAL analysis of a PAN European STOP tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study. ASH 2021; Abstract 633.

Marin D et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol;28(14):2381-8. Abstract

Mughal TI et al. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica 2021;106(7):1787-93. Abstract

Obeng-Kusi M et al. No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study). Leuk Res 2021;111:106734. Abstract

Pane F et al. International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission in patients with with chronic myeloid leukemia. EHA 2022; Abstract S156.

Rea D et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. ASCO 2022; Abstract 7004.